2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
|
EQS-News: Cannovum AG
/ Key word(s): Personnel
Berlin, 25.11.2022 - Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) expands its Management Board. The new board position of the first German fully licensed cannabis company on the stock exchange will be taken over by Klaus Madzia as of 25.11.2022. The long-time journalist and communications expert has been Chief Marketing Officer (CMO) for Cannovum AG since September 2022.
"We are very pleased to have Klaus Madzia, an experienced media and marketing professional, on the board," says Pia Marten, board member and co-founder of Cannovum AG. Marten adds, "With him, we can further expand our strong position for the legalization of the stimulant market and thus powerfully advance the cannabis revolution."
Klaus Madzia: "This is a unique opportunity: a new market worth billions is emerging in Europe. Cannabis is becoming the recreational choice of a young, innovative generation. Cannovum AG stands ready to become a major player in this emerging segment."
Klaus Madzia has worked as a journalist, editor-in-chief, and content director in various positions in Germany and Europe over the past 20 years. After starting as an editor at the news magazine DER SPIEGEL, he held positions at the media houses Condé Nast, Burda and Handelsblatt. Thanks to his many years of consulting work for Wort und Bild Verlag, the 55-year-old is very familiar with the digitization of the healthcare system.
Contact: Klaus Madzia, IR & PR, Cannovum AG Phone +49 30 3982 163 62, klaus.madzia@cannovum.com
Cannovum AG is the first German fully licensed cannabis company to be listed on the stock exchange. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, it is a fully licensed pharmaceutical wholesaler, importer, and manufacturer of high-quality medical cannabis products based in Berlin. Cannovum AG is ready for the legalization of cannabis and well prepared: for sales through pharmacies as well as through licensed specialty stores and online shipping. Cannovum AG is already a market leader in the medical cannabis sector. Currently, the company is active in the importation of high-quality cannabinoid precursors, medical-scientific education and nationwide distribution for a simplified and equitable access to cannabis-based therapies.
For more information, visit www.cannovum.de
25.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Cannovum AG |
| Rheinsberger Str. 76/77 | |
| 10115 Berlin | |
| Germany | |
| Phone: | +49 (0)30 3982 16360 |
| E-mail: | ir@cannovum.com |
| Internet: | www.cannovum.com |
| ISIN: | DE000A2LQU21 |
| WKN: | A2LQU2 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich |
| EQS News ID: | 1497791 |
| End of News | EQS News Service |
|
|
1497791 25.11.2022 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
